Bronchiolitis obliterans organizing pneumonia (BOOP)

AccessScience ◽  
2022 ◽  
Keyword(s):  
Bronchiolitis Obliterans ◽  
Organizing Pneumonia ◽  
Bronchiolitis Obliterans Organizing Pneumonia

Two Cases of Bronchiolitis Obliterans Organizing Pneumonia treated with Steroid and Cyclosporine therapy

2005 ◽  
Vol 59 (3) ◽  
pp. 315 ◽  
Author(s):  
Jong Hoo Lee ◽  
Myung Jae Park ◽  
Yi Hyung Kim ◽  
Byung Jo Park ◽  
Won Taek Oh ◽  
...  
Keyword(s):  
Bronchiolitis Obliterans ◽  
Organizing Pneumonia ◽  
Bronchiolitis Obliterans Organizing Pneumonia ◽  
Cyclosporine Therapy

Bronchiolitis obliterans organizing pneumonia after orthotopic liver transplantation

2004 ◽  
Vol 10 (3) ◽  
pp. 456-459 ◽  
Author(s):  
Roopa Kohli-Seth ◽  
Claude Killu ◽  
May Jennifer Amolat ◽  
John Oropello ◽  
Anthony Manasia ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Orthotopic Liver Transplantation ◽  
Bronchiolitis Obliterans ◽  
Organizing Pneumonia ◽  
Bronchiolitis Obliterans Organizing Pneumonia

scholarly journals Methotrexate-induced Pulmonary Toxicity Bronchiolitis Obliterans Organizing Pneumonia: A Rare Entity

2016 ◽  
Vol 1 (2) ◽  
pp. 64-65
Author(s):  
Gaurav Bhardwaj ◽  
Vikram Kumar Jain ◽  
Anubhav Sharma ◽  
Lokesh Maan
Keyword(s):  
Side Effects ◽  
Broad Spectrum ◽  
Bronchiolitis Obliterans ◽  
Pulmonary Toxicity ◽  
Rare Case ◽  
Organizing Pneumonia ◽  
Rare Entity ◽  
Mahatma Gandhi ◽  
Bronchiolitis Obliterans Organizing Pneumonia

ABSTRACT Methotrexate is one of the most widely used broad-spectrum immunomodulator. It can be used as a primary option or as in combination of drugs in various immunological conditions. Generally, it is safe when use in lower dosages. However, a clinician has to be alert regarding some of its less common but toxic side-effects. Here, we discuss a rare case who developed methotrexate-induced pulmonary toxicity. How to cite this article Mishra M, Jain VK, Sharma A, Bhardwaj G, Maan L. Methotrexate-induced Pulmonary Toxicity Bronchiolitis Obliterans Organizing Pneumonia: A Rare Entity. J Mahatma Gandhi Univ Med Sci Tech 2016;1(2):64-65.

scholarly journals Bronchiolitis Obliterans Organizing Pneumonia after Breast Cancer Radiotherapy and letrozole: A Case Report and Literature Review

2021 ◽  
Vol 4 (3) ◽  
pp. 01-05
Author(s):  
Alati Aurélia ◽  
Clavère Pierre ◽  
Leobon Sophie
Keyword(s):  
Conservative Treatment ◽  
Bronchiolitis Obliterans ◽  
Radiation Treatment ◽  
Ductal Carcinoma ◽  
New Drugs ◽  
Imaging Features ◽  
Organizing Pneumonia ◽  
Bronchiolitis Obliterans Organizing Pneumonia ◽  
Breast Cancer Radiotherapy ◽  
Imaging Results

Objectives: Bronchiolitis obliterans organizing pneumonia occurs with prevalence rate 1–3% after breast conservative treatment in series. In response to radiation of a lung or surrounding tissues, an inflammatory reaction can affect both lungs and is located within the radiation field. Characteristic imaging features include multiple alveolar opacities and diffuse ground-glass shadows. Letrozole may induce iatrogenic organizing pneumonia. Materials and methods: we report the case of a 76-year-old female who underwent conservative treatment for an invasive ductal carcinoma of the left breast. Hypofractionated radiotherapy was delivered with a total dose of 42.5 Gy in 16 sessions of 2.65 Gy using a three-dimensional technique. After the radiotherapy ended letrozole was indicated. Results: Several weeks after the radiotherapy ended and letrozole was introduced, she described a flu-like syndrome. Samples were negative, and there was no improvement after four courses of antibiotics. Imaging suggested bronchiolitis obliterans organizing pneumonia. Her symptomatology lessened after the letrozole was discontinued, and 11 months after radiotherapy finished, her imaging results were clear. Conclusion: Physicians must consider bronchiolitis obliterans organizing pneumonia. Cases may increase with hypofractionated radiation treatment and new drugs. Letrozole may potentiate the risk. Dosimetry may be adapted to the lung and subpleural areas for patients with risk factors and taking adjuvant or concurrent drugs with potential pneumotoxicity.

Sign in / Sign up

Export Citation Format

Share Document